Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
$64.57
+0.0%
$41.49
$6.71
$64.70
$4.23B1.141.93 million shs1.18 million shs
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.09
-29.8%
$0.15
$0.09
$1.25
$4.17M-0.244.54 million shs12.28 million shs
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$9.25
$9.22
$3.46
$9.28
$420.52M1.3840,890 shs178,496 shs
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$19.52
-1.3%
$18.93
$10.06
$21.72
$367.35M0.8250,586 shs37,071 shs
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$0.92
-1.1%
$1.02
$0.79
$4.05
$25.63M1.3328,313 shs7,563 shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
-0.05%+0.08%+64.08%+247.79%+801.54%
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
+3.00%+1.82%-11.38%-4.29%-86.25%
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.00%0.00%0.00%0.00%0.00%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
+1.85%+4.55%+0.15%+13.75%+86.69%
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
+2.81%+1.77%-1.91%-16.41%-73.44%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
1.4516 of 5 stars
2.13.00.00.02.74.20.0
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
2.4975 of 5 stars
2.55.00.80.01.81.71.3
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
2.8653 of 5 stars
3.85.00.00.00.01.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
2.27
Hold$50.33-22.05% Downside
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
3.00
BuyN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
3.00
Buy$24.0022.95% Upside
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
3.50
Strong Buy$8.00769.57% Upside

Current Analyst Ratings

Latest ALPN, KIN, SLGL, NATR, and ATXI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/16/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/12/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$42.00 ➝ $65.00
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $65.00
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Sector Perform$41.00 ➝ $65.00
4/11/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Peer Perform
4/9/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$55.00
3/19/2024
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $47.00
3/13/2024
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.50 ➝ $24.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
$58.88M71.88N/AN/A$5.64 per share11.45
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$0.03 per shareN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
$42.16M9.97N/AN/A$1.75 per share5.29
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$445.32M0.82$1.60 per share12.17$8.36 per share2.33
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
$1.55M16.54N/AN/A$1.67 per share0.55

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
-$32.18M-$0.64N/AN/AN/A-54.66%-15.54%-11.34%5/9/2024 (Estimated)
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M-$1.27N/AN/AN/AN/A-335.11%5/10/2024 (Estimated)
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$15.08M$0.7725.35N/A3.39%12.25%7.75%5/7/2024 (Confirmed)
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
-$27.24M-$1.01N/AN/AN/A-1,331.01%-61.52%-53.75%5/10/2024 (Estimated)

Latest ALPN, KIN, SLGL, NATR, and ATXI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/AN/A  
3/18/2024Q4 2023
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
-$0.32$0.15+$0.47$0.15$6.90 million$30.85 million
3/18/2024Q4 2023
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A$0.56+$0.56$0.56N/AN/A
3/13/2024Q4 2023
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
-$0.16-$0.17-$0.01-$0.17$0.27 million$0.45 million
3/12/2024Q4 2023
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A$0.45+$0.45$0.44N/A$108.94 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
N/AN/AN/AN/AN/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
N/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$0.402.05%N/A51.95%N/A
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
N/A
7.86
7.86
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
1.55
1.55
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
0.19
7.02
7.02
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A
2.16
1.29
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
N/A
9.10
9.10

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Alpine Immune Sciences, Inc. stock logo
ALPN
Alpine Immune Sciences
14265.55 million37.82 millionOptionable
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
344.26 million43.46 millionNot Optionable
Kindred Biosciences, Inc. stock logo
KIN
Kindred Biosciences
6345.46 millionN/AOptionable
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
81418.82 million17.90 millionOptionable
Sol-Gel Technologies Ltd. stock logo
SLGL
Sol-Gel Technologies
3627.86 million9.33 millionOptionable

ALPN, KIN, SLGL, NATR, and ATXI Headlines

SourceHeadline
Sol-Gel Technologies Ltd.Sol-Gel Technologies Ltd.
wsj.com - April 20 at 5:36 PM
Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 17.8% in MarchSol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 17.8% in March
americanbankingnews.com - April 15 at 5:40 AM
Sol-Gels Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® CreamSol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
globenewswire.com - April 1 at 7:00 AM
Sol Gel Technologies Ltd (SLGL)Sol Gel Technologies Ltd (SLGL)
investing.com - March 23 at 11:58 AM
SLGL May 2024 2.500 putSLGL May 2024 2.500 put
finance.yahoo.com - March 16 at 1:25 PM
Sol-Gel Technologies: Q4 Earnings InsightsSol-Gel Technologies: Q4 Earnings Insights
benzinga.com - March 14 at 1:48 PM
Sol-Gel Technologies Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineSol-Gel Technologies Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
finance.yahoo.com - March 14 at 8:47 AM
Sol-Gel Technologies Ltd.: Sol-Gel Reports Full-Year 2023 Financial Results and Corporate DevelopmentsSol-Gel Technologies Ltd.: Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
finanznachrichten.de - March 14 at 3:47 AM
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate DevelopmentsSol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
globenewswire.com - March 13 at 7:00 AM
Sol-Gel Technologies Ltd. (SLGL) stock forecast and price targetSol-Gel Technologies Ltd. (SLGL) stock forecast and price target
finance.yahoo.com - February 28 at 9:43 AM
Sol-Gel Technologies Stock (NASDAQ:SLGL), Quotes and News SummarySol-Gel Technologies Stock (NASDAQ:SLGL), Quotes and News Summary
benzinga.com - February 22 at 10:05 AM
Optimistic Buy Rating for Sol-Gel Technologies on Revolutionary Topical Treatment SGT-610’s Market PotentialOptimistic Buy Rating for Sol-Gel Technologies on Revolutionary Topical Treatment SGT-610’s Market Potential
markets.businessinsider.com - December 9 at 3:48 AM
Sol-Gel Technologies Ltd.: Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 StudySol-Gel Technologies Ltd.: Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
finanznachrichten.de - November 30 at 6:30 PM
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 StudySol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
finance.yahoo.com - November 30 at 8:29 AM
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
finance.yahoo.com - November 28 at 9:36 AM
Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?
finance.yahoo.com - November 20 at 7:19 AM
Sol-Gel Technologies GAAP EPS of -$0.21 beats by $0.02, revenue of $0.21M misses by $0.48MSol-Gel Technologies GAAP EPS of -$0.21 beats by $0.02, revenue of $0.21M misses by $0.48M
msn.com - November 9 at 5:31 PM
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateSol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 7:27 AM
Zacks Industry Outlook Highlights Dr. Reddys Laboratories, Amphastar Pharmaceuticals and Sol-Gel TechnologiesZacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies
finance.yahoo.com - October 31 at 9:35 AM
Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Invest In Growth?Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Invest In Growth?
finance.yahoo.com - October 10 at 10:05 AM
Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceSol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
finance.yahoo.com - August 30 at 2:55 PM
HC Wainwright & Co. Maintains Sol-Gel Technologies (SLGL) Buy RecommendationHC Wainwright & Co. Maintains Sol-Gel Technologies (SLGL) Buy Recommendation
msn.com - August 15 at 5:07 AM
Expert Ratings for Sol-Gel TechnologiesExpert Ratings for Sol-Gel Technologies
markets.businessinsider.com - August 11 at 4:26 PM
Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue EstimatesSol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 10 at 2:04 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Alpine Immune Sciences logo

Alpine Immune Sciences

NASDAQ:ALPN
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.
Avenue Therapeutics logo

Avenue Therapeutics

NASDAQ:ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Kindred Biosciences logo

Kindred Biosciences

NASDAQ:KIN
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.
Nature

Nature's Sunshine Products

NASDAQ:NATR
Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.
Sol-Gel Technologies logo

Sol-Gel Technologies

NASDAQ:SLGL
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.